Quarterly Appendix 4C and Activities Report
Open PDF
| Stock | Island Pharmaceuticals Ltd (ILA.ASX) |
|---|---|
| Release Time | 30 Jul 2026, 9:47 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Island Pharmaceuticals Ltd. Announces Progress in Galidesivir Development
Key Points
- GMP manufacturing of Galidesivir underway for pivotal Marburg studies
- Expanded CRADA with USAMRIID for FDA-directed dose optimization study
- FDA Orphan Drug Designation for Galidesivir for Marburg virus
- Regulatory approvals secured for Galidesivir use in Bundibugyo Ebola outbreak
- Singapore patent granted for ISLA-101 to treat flavivirus infections
Full Summary
Island Pharmaceuticals Ltd. is pleased to provide a summary of activities undertaken during the three-month period ended 30 June 2026. Key achievements include the commencement of GMP manufacturing of Galidesivir to support pivotal Marburg studies, an expanded CRADA with USAMRIID for dose optimization, FDA Orphan Drug Designation for Galidesivir for Marburg virus, regulatory approvals for Galidesivir use during the Bundibugyo Ebola outbreak in Uganda, and a Singapore patent for ISLA-101 to treat flavivirus infections. These initiatives demonstrate the significant momentum across the Galidesivir program, positioning Island at the forefront of efforts to develop a broad-spectrum antiviral for high-consequence viral threats.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In